Glaxosmithkline Share News (GSK)

LONDON MORNING BRIEFING: CRH And TSB Lead Firm Early Market

FDA Panel Recommends Approval Of GSK Asthma Drug For Adults

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents

(Adds details, background, analyst comment, paragraphs 4-13) By Toni Clarke March 19 (Reuters) - GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough for adults with asthma to use but not adolescents, an advisory panel to the U.S. Food and Drug A

FDA panel backs Glaxo asthma drug for adults, not adolescents

March 19 (Reuters) - GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough to be approved in adults with asthma but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The panel voted 16 to 4 that the produ

GSK sale of Aspen stake a 'credit positive' move, says Moody's

Rating agency Moody's has described GlaxoSmithKline's decision to sell a 6.2% stake in Aspen Pharmacare as "credit positive". On 13 March, the pharmaceutical giant sold half of its 12.4% stake in South Africa-based Aspen Pharmacare Holdings for £574m, in what Moody's described as a "credit-positive

FDA panel to discuss Ebola vaccine development in May

March 18 (Reuters) - The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. The federal health regulator would discuss the develop

UPDATE 2-FDA staff finds no new safety problems with Glaxo's asthma drug

(Adds details on Theravance deal, analyst comment, background) March 17 (Reuters) - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration

FDA staff finds no new safety problems with Glaxo's asthma drug

March 17 (Reuters) - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two days ahead of a meeting of FDA advisers to di

Glaxo Starts Phase III Programme For Retosiban In Premature Births

Ebola booster vaccine trial to combine GSK, Emergent Bio shots

LONDON, March 16 (Reuters) - Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions . The Maryland-based biotech company said on Monday

FTSE 250 movers: Afren plummets on looming dilution, Diploma higher on Kubo deal

Shares in Afren tumbled after the struggling oil and gas group proposed a debt-for-equity swap with creditors to address its funding needs and recapitalise . The company said it "will result in substantial dilution for existing shareholders", and if shareholders don't approve the plan, the company w

UK MIDDAY BRIEFING: Oil, Energy Companies Under Renewed Pressure

London midday: Markets slip after weak construction data, utilities fall

Stocks in London dipped into the red on Friday morning after data showed an unexpected decline in UK construction output, while utility shares weakened on political uncertainty. The FTSE 100 was down 0.35% at 6,737.10 by midday with SSE and Centrica among the worst performers. Construction output d

TOP NEWS: UK Construction Output Falls Unexpectedly In January

London open: Stock markets flat ahead of quiet day

UK stocks were more or less flat in early deals on Friday ahead of a quiet day for the markets in terms of economic data and corporate news. London's FTSE 100 was trading up just 0.01% at 6,761.79 early on. As it stands, the Footsie is still nearly 3% lower than where it stood last Friday as a stre